Adherence to interferon-beta treatment and results of therapy switching

This publication has 22 references indexed in Scilit:

• Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis
  Multiple Sclerosis Journal, 2005
• Twenty‐four‐month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone^®)
  European Journal of Neurology, 2005
• Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns
  Multiple Sclerosis Journal, 2005
• High-dose, frequently administered interferon beta therapy for relapsing–remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study
  Journal of the Neurological Sciences, 2004
• Long-term interferon-β treatment for multiple sclerosis
  Neurological Sciences, 2003
• A post-marketing study on interferon 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients
  Journal of Neurology, Neurosurgery & Psychiatry, 2003
• Interrupted therapy
  Neurology, 2003
• Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]
  Neurology, 2002
• Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS
  Neurology, 2000
• Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment
  Multiple Sclerosis Journal, 1996